首页> Annals of oncology : official journal of the European Society for Medical Oncology> Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].

Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].

导出原文传递

翻译打印收藏纠错

第一作者： D J,Slamon

第一单位： David Geffen School of Medicine at UCLA, Los Angeles, USA. Electronic address: dslamon@mednet.ucla.edu.

作者： D J,Slamon ^[1] ; P,Neven ^[2] ; S,Chia ^[3] ; G,Jerusalem ^[4] ; M,De Laurentiis ^[5] ; S,Im ^[6] ; K,Petrakova ^[7] ; G,Valeria Bianchi ^[8] ; M,Martín ^[9] ; A,Nusch ^[10] ; G S,Sonke ^[11] ; L,De la Cruz-Merino ^[12] ; J T,Beck ^[13] ; Y,Ji ^[14] ; C,Wang ^[15] ; U,Deore ^[14] ; A,Chakravartty ^[14] ; J P,Zarate ^[14] ; T,Taran ^[15] ; P A,Fasching ^[16]

作者单位： David Geffen School of Medicine at UCLA, Los Angeles, USA. Electronic address: dslamon@mednet.ucla.edu. ^[1] Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium. ^[2] British Columbia Cancer Agency, Vancouver, Canada. ^[3] CHU Liege and Liège University, Liège, Belgium. ^[4] Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy. ^[5] Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. ^[6] Masaryk Memorial Cancer Institute, Brno, Czech Republic. ^[7] Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy. ^[8] Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid, Spain. ^[9] Practice for Hematology and Internal Oncology, Velbert, Germany. ^[10] Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, The Netherlands. ^[11] Hospital Universitario Virgen Macarena, Seville, Spain. ^[12] Highlands Oncology Group, Fayetteville, USA. ^[13] Novartis Pharmaceuticals Corporation, East Hanover, USA. ^[14] Novartis Pharma AG, Basel, Switzerland. ^[15] Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen, Erlangen, Germany. ^[16]

DOI 10.1016/j.annonc.2021.07.011

PMID 34412950

发布时间 2021-09-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交